Addex Reports Third Quarter 2024 Financial Results and Provides Corporate Update
Portfolio Pulse from
Addex Therapeutics reported its Q3 2024 financial results and announced that Indivior has selected its GABA B PAM drug candidate for development in substance use disorders, starting IND enabling studies.
November 22, 2024 | 6:15 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Addex Therapeutics announced its Q3 2024 financial results and a significant development with Indivior selecting its GABA B PAM drug candidate for substance use disorders, initiating IND enabling studies.
The selection of Addex's GABA B PAM drug candidate by Indivior for development in substance use disorders is a positive development, likely to boost investor confidence and potentially increase the stock price. The initiation of IND enabling studies marks a significant step forward in the drug's development process.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 90